Sangamo Biosciences Has Option to Acquire Gendaq in Stock Deal Worth $40M

May 30, 2001

NEW YORK, May 30 - Sangamo Biosciences said Wednesday it has obtained the option to acquire privately-held Gendaq in a stock-for-stock deal worth $39.7 million.

Sangamo, which is currently completing due diligence, has until July 14 to exercise its option to acquire Gendaq, a London-based developer of zinc finger DNA binding proteins for gene regulating gene expression.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

A Winning Diagnostic

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

This Week in Science

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Main menu